Earnings summaries and quarterly performance for BRUKER.
Executive leadership at BRUKER.
Frank H. Laukien
Detailed
Chairman, President and Chief Executive Officer
CEO
BA
Burkhard A. Prause
Detailed
President and Chief Executive Officer, Bruker Energy & Supercon Technologies, Inc.
FB
Falko Busse
Detailed
President, Bruker BioSpin Group
GN
Gerald N. Herman
Detailed
Executive Vice President and Chief Financial Officer
JW
Juergen W. Srega
Detailed
President, Bruker CALID Group and Bruker Daltonics Division
MR
Mark R. Munch
Detailed
Executive Vice President, President of Bruker NANO Group and Bruker NANO Surfaces Division
Board of directors at BRUKER.
AQ
Adelene Q. Perkins
Detailed
Director
BH
Bonnie H. Anderson
Detailed
Director
CM
Cynthia M. Friend
Detailed
Director
HF
Hermann F. Requardt
Detailed
Director
JA
John A. Ornell
Detailed
Director
LA
Laura A. Francis
Detailed
Director
RA
Richard A. Packer
Detailed
Lead Independent Director
RJ
Robert J. Rosenthal
Detailed
Director
WA
William A. Linton
Detailed
Director
Research analysts who have asked questions during BRUKER earnings calls.
Luke Sergott
Barclays
4 questions for BRKR
Also covers: A, AVTR, CERT +19 more
Patrick Donnelly
Citi
4 questions for BRKR
Also covers: A, AVTR, BIO +22 more
PS
Puneet Souda
Leerink Partners
4 questions for BRKR
Also covers: A, ABCL, CSTL +20 more
Tycho Peterson
Jefferies
4 questions for BRKR
Also covers: A, AVTR, BIO +22 more
Michael Ryskin
Bank of America Merrill Lynch
3 questions for BRKR
Also covers: A, ALGN, AVTR +28 more
RV
Rachel Vatnsdal Olson
JPMorgan
3 questions for BRKR
Also covers: A, ADPT, AKYA +14 more
Daniel Brennan
TD Cowen
2 questions for BRKR
Also covers: A, ADPT, AVTR +24 more
Joshua Waldman
Cleveland Research Company
2 questions for BRKR
Also covers: A, CRL, ICLR +1 more
SB
S. Brandon Couillard
Wells Fargo Securities, LLC
2 questions for BRKR
Also covers: A, WAT
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for BRKR
Also covers: AKYA, CSTL, CYRX +15 more
Brandon Couillard
Wells Fargo & Company
1 question for BRKR
Also covers: A, AVTR, BIO +10 more
Douglas Schenkel
Wolfe Research, LLC
1 question for BRKR
Also covers: A, AVTR, DHR +21 more
Doug Schenkel
Wolfe Research LLC
1 question for BRKR
Also covers: A, AVTR, DHR +15 more
MN
Marta Nazarovets Zaremba
JPMorgan Chase & Co.
1 question for BRKR
Also covers: SEER
Subbu Nambi
Guggenheim Securities
1 question for BRKR
Also covers: BOLD, CARS, CSTL +16 more
Recent press releases and 8-K filings for BRKR.
Bruker Corporation Provides Preliminary Q4 2025 Revenue and FY 2026 Outlook
BRKR
Earnings
Guidance Update
- Bruker Corporation announced on January 12, 2026, its preliminary expectation for revenue for the fourth quarter ended December 31, 2025, to be between $965 million and $970 million.
- The Bruker Scientific Instruments segments book-to-bill ratio for Q4 2025 was above 1.0.
- For the full year ending December 31, 2026, the company provided a preliminary outlook for organic revenue growth of flat to up low-single digits, non-GAAP organic operating margins to expand 250 to 300 basis points, and non-GAAP earnings per share to grow in the double-digits, all compared to full year 2025.
Jan 12, 2026, 5:00 PM
Bruker Corporation Provides 2026 Outlook and Strategic Focus at J.P. Morgan Conference
BRKR
Guidance Update
New Projects/Investments
Demand Weakening
- Bruker Corporation reported preliminary Q4 2025 revenue between $965 million and $970 million and full-year 2025 reported revenue of approximately $3.43 billion, representing about 2% growth.
- Following a "rough year" in 2025, Bruker's focus for 2026 and the next three to five years is on profitability, aiming for a transformative margin and EPS jump from mid-teens to low to mid-20s margins and double-digit EPS growth.
- The company anticipates $120 million in anticipated cost savings in 2026, contributing to a preliminary 2026 outlook of flat to low single-digit organic revenue growth (constant exchange rate), 250-300 basis points organic operating profit margin expansion, and double-digit non-GAAP EPS growth.
- Bruker is evolving "Project Accelerate" into "Project Accelerate 3.0," emphasizing aftermarket and sticky revenues and expanding into new opportunities in clinical microbiology, molecular diagnostics (a $500 million business), and automated AI lab tools (a $100 million business).
- Recent product launches, including the TIMS Omni and TIMS Metabo mass spectrometers and the CosMx Whole Transcriptome Panel, are showing good traction, with the Wave Rapid AST platform anticipated for a U.S. launch in 2026 pending FDA clearance.
Jan 12, 2026, 5:00 PM
Bruker Discusses 2025 Performance and 2026 Strategic Focus
BRKR
Guidance Update
Product Launch
New Projects/Investments
- Bruker reported preliminary Q4 2025 revenue between $965 million and $970 million, contributing to a full-year 2025 preliminary revenue of approximately $3.43 billion, up about 2%. The company noted 2025 was a "rough year" with organic revenue down, but constant exchange rate revenue was flat.
- For 2026, Bruker's strategic focus is on profitability, aiming for a transformative margin and EPS jump, with a goal to increase margins from the mid-teens to the low to mid-20s and deliver double-digit EPS growth over the next three to five years.
- The company is targeting $120 million in cost savings for 2026, encompassing both COGS and OPEX, to drive significant margin improvement and double-digit EPS growth.
- The preliminary outlook for 2026 includes flat to low single-digit organic revenue growth (non-GAAP constant exchange rate), 250-300 basis points of organic operating profit margin expansion, and double-digit non-GAAP EPS growth.
- Bruker highlighted new product launches, such as the TIMS Omni and CosMx Whole Transcriptome Panel, and strategic opportunities in clinical microbiology, molecular diagnostics for infectious diseases, and automated AI lab tools as key growth drivers.
Jan 12, 2026, 5:00 PM
Bruker Provides 2026 Outlook and Strategic Update at J.P. Morgan Conference
BRKR
Guidance Update
New Projects/Investments
Product Launch
- Bruker reported preliminary Q4 2025 revenue between $965 million and $970 million, approximately $10 million above consensus, with full-year 2025 reported revenue reaching about $3.43 billion, an increase of 2%. The book-to-bill ratio for its BSI segment was just above 1.0 in Q4 2025.
- For 2026, the company anticipates flat to low single-digit organic revenue growth at constant exchange rates, while aiming for 250-300 basis points of organic operating profit margin expansion and double-digit non-GAAP EPS growth. These improvements are expected to be driven by $120 million in cost reductions across COGS and OPEX.
- Bruker is evolving Project Accelerate into Project Accelerate 3.0, with a focus on profitability, transformative margin, and sticky aftermarket revenues. Key growth areas include clinical microbiology and molecular diagnostics (an approximately $500 million business with 65-75% aftermarket revenue and above-average margins), automated AI lab tools (currently generating about $100 million in revenue), and defense detection.
- The company's spatial biology business grew in low double digits in 2025, and it launched new multi-omics mass spectrometers, including the TIMS Omni, a $1.5 million instrument that has already received orders from biopharma. Bruker also plans to launch the Wave Rapid AST platform in the U.S. market in 2026, pending FDA clearance.
Jan 12, 2026, 5:00 PM
Bruker outlines FY26 outlook and strategic shift to profit focus at J.P. Morgan Healthcare Conference
BRKR
Guidance Update
New Projects/Investments
Demand Weakening
- Bruker reported preliminary Q4 2025 revenue of $965M - $970M, leading to an implied FY25 revenue of ~$3.43B, up ~2%. The company noted that FY2025 was challenging due to macro and market headwinds, impacting growth, margins, and EPS.
- For FY2026, Bruker anticipates flat to low single-digit (LSD) organic revenue growth, an expansion of organic operating profit margin (OPM) by 250-300 basis points, and double-digit EPS growth. This outlook includes $120M of anticipated cost savings.
- The company is shifting its focus from a 70% revenue jump from FY2020-2024 to a transformative margin and EPS jump for FY2026-2030.
- Bruker is expanding its leadership in post-genomic discovery solutions and pursuing Project Accelerate 3.0, which adds high-growth, high-margin opportunities in Novel Molecular Diagnostics, Automated AI-Labs, and Defense Detection.
Jan 12, 2026, 5:00 PM
Bruker Announces $500 Million in Multi-Year Superconductor Orders
BRKR
New Projects/Investments
Revenue Acceleration/Inflection
- Bruker's Energy & Supercon Technologies (BEST) division announced two multi-year supply agreements for high-performance superconductors used by global radiology companies for MRI magnets.
- The combined order value of these agreements is approximately $500 million in expected future BEST revenues.
- These agreements are expansions of previous superconductor supply framework agreements.
- One of the agreements extends for up to seven years.
Jan 9, 2026, 12:00 PM
Bruker Consolidates Ownership of TOFWERK
BRKR
M&A
New Projects/Investments
- Bruker Corporation has consolidated its ownership of TOFWERK AG to 100% by acquiring an additional 60% stake.
- TOFWERK is a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology, which expands Bruker's portfolio into new applied markets such as air quality monitoring and semiconductor cleanroom monitoring.
- TOFWERK, founded in 2002, is profitable, has 130 employees, and reported 2025 revenues of approximately $40 million.
Jan 8, 2026, 12:00 PM
Bruker Discusses Q3 2025 Results, Biopharma Growth, and Strategic Focus
BRKR
Guidance Update
Product Launch
M&A
- Bruker reported a mixed Q3 2025, with order bookings exceeding revenue (book-to-bill ratio over one), but revenue was down 4.7% and EPS fell 25% year-over-year to $0.45. Profitability was impacted by U.S. academic/government weakness, China stimulus delays, tariffs, and foreign exchange.
- The company sees strong order performance in biopharma and expects China revenue to grow in 2026 after a decline in 2025, driven by biopharma and industrial segments. New product launches, TIMS Omni and TIMS Metabo (introduced June 2025), have received early orders, with revenue recognition anticipated in Q2 or Q3 2026.
- The ELITechGroup acquisition (April 2024) is performing well, contributing approximately $190 million in 2025 revenues and expanding Bruker's molecular diagnostics business to roughly $500 million with a focus on sustainable recurring revenue.
- Bruker's capital deployment strategy prioritizes R&D and CapEx, with a focus on debt reduction to achieve a leverage ratio closer to 2.7 from the current ~3. Large acquisition activity is not planned in the short term.
Dec 10, 2025, 10:00 AM
Bruker Discusses Q3 2025 Performance and Future Strategy
BRKR
Earnings
Guidance Update
M&A
- Bruker reported a mixed third quarter 2025, with a book-to-bill ratio of over one and revenue over $860 million, but revenue was down about 4.7% and EPS at $0.45 was down about 25% year-over-year. Profitability was challenged by U.S. academic/government weakness, China stimulus funding delays, tariffs, and foreign exchange.
- Order performance showed significant strength in academic and government research outside the U.S. and in biopharma, with biopharma momentum continuing into Q4. The company expects muted performance in the U.S. academic and government segment for 2026, looking to Europe, Japan, and China for growth.
- China, representing 13%-15% of total revenue, saw declining revenue over the past 1.5 years, expected to be down in the low single digits for 2025, but showed solid order performance in Q3 2025 and is anticipated to grow in 2026, particularly in biopharma and industrial segments.
- New mass spectrometry products, timsOmni and timsMetabo, launched in June 2025, have already received orders in Q3 2025, with revenue recognition expected in Q2 or Q3 2026, and are projected to significantly contribute to revenue in 2026 and beyond.
- The April 2024 acquisition of ELITechGroup is performing well, expected to contribute $190 million in revenues for 2025, expanding Bruker's molecular diagnostics business to roughly $500 million and providing a valuable recurring revenue stream. Bruker is currently on a "deal diet" for large M&A, prioritizing R&D, CapEx, and debt reduction to a leverage ratio of 2.7 from the current 3.
Dec 10, 2025, 10:00 AM
Bruker Discusses Q3 2025 Results, Market Dynamics, and Strategic Focus at Nasdaq Investor Conference
BRKR
Guidance Update
Product Launch
M&A
- Bruker reported a mixed third quarter of 2025, with a book-to-bill ratio of over one and revenue of over $860 million, but revenue was down 4.7% and EPS was $0.45, a 25% year-over-year decrease, primarily due to U.S. ACAGOV weakness, China stimulus delays, tariffs, and foreign exchange impacts.
- The company observed strong order performance in academic and government research outside the U.S. and in biopharma, with biopharma exposure between 15%-20% of total revenue and positive traction expected in Japan, China, and Europe. China, representing 13%-15% of total revenue, is expected to see year-over-year growth in 2026 from a weak 2025 comparative base.
- Bruker launched new mass spectrometry products, TIMS Omni and TIMS Metabo, in June 2025, which have already received orders and are expected to contribute significantly to revenue from Q2 or Q3 2026.
- Following the April 2024 acquisition of ELITechGroup, projected to generate $190 million in revenues for 2025, Bruker aims to grow its molecular diagnostics business to approximately $500 million through sustainable recurring revenue. The company is currently on a "deal diet" for large M&A, prioritizing R&D, CapEx, and debt reduction to achieve a leverage ratio of 2.7 from the current 3.
Dec 10, 2025, 10:00 AM
Quarterly earnings call transcripts for BRUKER.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more